Drugs / T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine
T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00972309 | May 2009 → Feb 2015 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00972309 ↗ |
| Modality | Cell therapy | “vaccination with TARP peptide-pulsed autologous dendritic cells (DCs)” NCT00972309 ↗ |